Cerity Partners
TXG icon

Cerity Partners’s 10x Genomics TXG Stock Holding History

Cerity Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Sell
81,712
-52,115
-39% -$1.37M ﹤0.01% 1327
2026
Q1 		$2.84M Buy
133,827
+4,576
+4% +$91.5K ﹤0.01% 1287
2025
Q4 		$2.11M Sell
129,251
-4,103
-3% -$62K ﹤0.01% 1354
2025
Q3 		$1.56M Sell
133,354
-7,418
-5% -$96.7K ﹤0.01% 1401
2025
Q2 		$1.63M Buy
140,772
+114,407
+434% +$1.04M ﹤0.01% 1306
2025
Q1 		$230K Sell
26,365
-3,663
-12% -$46.2K ﹤0.01% 2149
2024
Q4 		$451K Sell
30,028
-6,339
-17% -$100K ﹤0.01% 1822
2024
Q3 		$821K Buy
36,367
+10,815
+42% +$224K ﹤0.01% 1501
2024
Q2 		$497K Buy
25,552
+555
+2% +$14.5K ﹤0.01% 1548
2024
Q1 		$938K Buy
24,997
+10,500
+72% +$461K ﹤0.01% 1306
2023
Q4 		$811K Buy
+14,497
New +$631K ﹤0.01% 1062
2023
Q2 		– Sell
-14,183
Closed -$790K – 1949
2023
Q1 		$790K Sell
14,183
-869
-6% -$40.6K ﹤0.01% 1083
2022
Q4 		$548K Sell
15,052
-133
-0.9% -$4.35K ﹤0.01% 901
2022
Q3 		$432K Sell
15,185
-1,636
-10% -$62.3K 0.01% 768
2022
Q2 		$761K Buy
16,821
+338
+2% +$17.5K 0.01% 615
2022
Q1 		$1.25M Buy
16,483
+14,491
+727% +$1.27M 0.02% 408
2021
Q4 		$296K Buy
1,992
+416
+26% +$63.7K ﹤0.01% 773
2021
Q3 		$229K Buy
1,576
+127
+9% +$21.8K 0.01% 622
2021
Q2 		$284K Buy
1,449
+202
+16% +$36.6K 0.01% 598
2021
Q1 		$226K Buy
+1,247
New +$215K 0.01% 627

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cerity Partners's TXG Position: Q2 2026 in Review

Cerity Partners reduced its 10x Genomics (TXG) stake by 39% in Q2 2026, selling an estimated $1.37M and leaving 81,712 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1327.

Cerity Partners first reported a position in TXG in Q1 2021 and has held it in 20 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Cerity Partners held 81,712 shares of 10x Genomics worth $3.13M as of Q2 2026.
  • Cerity Partners sold 52,115 10x Genomics shares in Q2 2026, an estimated $1.37M.
  • 10x Genomics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1327 holding.
  • Cerity Partners first reported a position in 10x Genomics in Q1 2021 and has held it in 20 quarters since.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.